Rockefeller Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $229K | Buy |
+25,542
| New | +$229K | ﹤0.01% | 1698 |
|
|
2024
Q4 | – | Sell |
-26,400
| Closed | -$201K | – | 1658 |
|
|
2024
Q3 | $201K | Buy |
+26,400
| New | +$201K | ﹤0.01% | 1606 |
|
|
2023
Q1 | – | Sell |
-3,800
| Closed | -$43K | – | 2155 |
|
|
2022
Q4 | $43K | Hold |
3,800
| – | – | ﹤0.01% | 2450 |
|
|
2022
Q3 | $47K | Hold |
3,800
| – | – | ﹤0.01% | 2379 |
|
|
2022
Q2 | $40K | Sell |
3,800
-28
| -0.7% | -$295 | ﹤0.01% | 2391 |
|
|
2022
Q1 | $62K | Buy |
3,828
+28
| +0.7% | +$454 | ﹤0.01% | 2198 |
|
|
2021
Q4 | $52K | Hold |
3,800
| – | – | ﹤0.01% | 2198 |
|
|
2021
Q3 | $54K | Hold |
3,800
| – | – | ﹤0.01% | 2098 |
|
|
2021
Q2 | $60K | Hold |
3,800
| – | – | ﹤0.01% | 1992 |
|
|
2021
Q1 | $38K | Buy |
3,800
+500
| +15% | +$5K | ﹤0.01% | 2002 |
|
|
2020
Q4 | $24K | Hold |
3,300
| – | – | ﹤0.01% | 1926 |
|
|
2020
Q3 | $11K | Hold |
3,300
| – | – | ﹤0.01% | 1978 |
|
|
2020
Q2 | $16K | Hold |
3,300
| – | – | ﹤0.01% | 1736 |
|
|
2020
Q1 | $7K | Buy |
+3,300
| New | +$7K | ﹤0.01% | 1844 |
|